Table 5.

Percentage LVFS measurements for Groups 1, 2, 3, 4, and 5 at various timepoints.

Left Ventricular Fractional Shortening (LVFS) Shown as %
	Group 1 (Control)	Group 2 (AT1-HSA-MRN-NPs—i.v. Injection)	Group 3 (MRN Lactate—i.v. Injection)	Group 4 (Empty NPs)	Group 5 AT1-HSA-MRN-NPs—Subcutaneous Injection)
Baseline—Pre-Ligation	52.6 ± 2.9	53.6 ± 2.1	52.6 ± 2.7	51.1 ± 1.3	54.6 ± 2.2
48 h Post Ligation	33.1 ± 1.5	29.8 ± 1.0	34.3 ± 2.7	31.2 ± 1.3	30.7 ± 2.5
60 min Post Injection	32.8 ± 1.7	50.1 ± 3.8 **	45.6 ± 3.2 **	34.7 ± 4.0	47.1 ± 3.9 **
24 h Post Injection	31.5 ± 1.2	50.4 ± 3.1 ***	33.6 ± 3.9	30.9 ± 2.4	40.5 ± 2.8 **
48 h Post Injection	31.7 ± 1.0	46.5 ± 3.1 **	30.2 ± 3.9	30.1 ± 1.5	34.8 ± 1.7
1-week Post Injection	31.3 ± 1.5	37.0 ± 2.7	30.8 ± 2.8	29.6 ± 1.1	35.9 ± 3.1

The data have been presented as mean ± SD (n = 5). The data have been presented as mean ± SD (n = 5). *** p < 0.001, ** p < 0.01, were considered significant based on Tukey’s post hoc analysis. The comparisons are with respect to the control Group 1.